Cinclus Pharma announces the first patient randomized in the Phase II study for X842 in GERD.
Stockholm, Sweden: Cinclus Pharma Holding AB (“Cinclus Pharma”), a biopharmaceutical company focused on the development of a novel treatment for severe gastroesophageal reflux disease (“GERD”), today announced that the first patient has been randomized in the Phase II dose ranging study for its lead candidate drug X842.This is a randomized double-blind, double dummy, active comparator-controlled dose-finding study. The study will be conducted in the USA and in seven countries in Europe at approximately 60 sites. The primary objective of the study is to support dose selection of X842, for